Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 102-106

  Wang, Hon Pin ^a   Hsu, Tsai Ching ^b   Hsu, Gwo Jong ^a   Li, Sin Lun ^b   Tzang, Bor Show ^b  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Neuropsychiatric; NOS (Nitric Oxide Synthase); SLE (systemic lupus erythematosus); TLR (toll like receptor)

Indexed keywords

CYSTAMINE; HEAT SHOCK PROTEIN 90; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; P21 ACTIVATED KINASE; PHOSPHATE BUFFERED SALINE; PROTEIN P53; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BAGG ALBINO MOUSE; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; MOUSE; NEUROPROTECTION; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE LEVEL;

ANIMALS; BRAIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTAMINE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HSP90 HEAT-SHOCK PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; TOLL-LIKE RECEPTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62149085555     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.039     Document Type: Article

References (48)

1. Abdollahi-Roodsaz S., Joosten L.A., Roelofs M.F., Radstake T.R., Matera G., Popa C., van der Meer J.W., Netea M.G., and van den Berg W.B. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56 (2007) 2957-2967
2. Abramson S.B., Amin A.R., Clancy R.M., and Attur M. The role of nitric oxide in tissue destruction. Best. Pract. Res. Clin. Rheumatol. 15 (2001) 831-845
3. Babbedge R.C., Bland-Wart P.A., Hart S.L., and Moore P.K. Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br. J. Pharmacol. 110 (1993) 225-228
4. Bandholtz L., Guo Y., Palmberg C., Mattsson K., Ohlsson B., High A., Shabanowitz J., Hunt D.F., Jörnvall H., Wigzell H., Agerberth B., and Gudmundsson G.H. Hsp90 binds CpG oligonucleotides directly: implications for hsp90 as a missing link in CpG signaling and recognition. Cell. Mol. Life Sci. 60 (2003) 422-429
5. Barrat F.J., and Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223 (2008) 271-283
6. Belmont H.M., Levartovsky D., Goel A., Amin A., Giorno R., Rediske J., Skovron M.L., and Abramson S.B. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 40 (1997) 1810-1816
7. Bender A.T., Silverstein A.M., Demady D.R., Kanelakis K.C., Noguchi S., Pratt W.B., and Osawa Y. Neuronal nitric-oxide synthase is regulated by the Hsp90-based chaperone system in vivo. J. Biol. Chem. 274 (1999) 1472-1478
8. Bostanci M.O., and Baǧirici F. Neuroprotection by 7-nitroindazole against iron-induced hippocampal neurotoxicity. Cell. Mol. Neurobiol. 27 (2007) 933-941
9. Carr R.I., Shucard D.W., Hoffman S.A., Hoffman A.W., Bardana E.J., and Harbeck R.J. Birth Defects Orig. Artic. Ser. 14 (1978) 209-235
10. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., and Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006) 417-428
11. De Jager P.L., Richardson A., Vyse T.J., and Rioux J.D. Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum. 54 (2006) 1279-1282
12. De Nardo D., Masendycz P., Ho S., Cross M., Fleetwood A.J., Reynolds E.C., Hamilton J.A., and Scholz G.M. A central role for the Hsp90.Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors. J. Biol. Chem. 280 (2005) 9813-9822
13. Elfering S.L., Sarkela T.M., and Giulivi C. Biochemistry of mitochondrial nitric-oxide synthase. J. Biol. Chem. 277 (2002) 38079-38086
14. Feinglass E.J., Arnett F.C., Dorsch C.A., Zizic T.M., and Stevens M.B. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 55 (1976) 323-339
15. Folk J.E. Transglutaminases. Annu. Rev. Biochem. 49 (1980) 517-531
16. Futrell N., Schultz L.R., and Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology 42 (1992) 1649-1657
17. García-Cardeña G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A., and Sessa W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature ( Lond. ) 392 (1998) 821-824
18. Gilkeson G.S., Mudgett J.S., Seldin M.F., Ruiz P., Alexander A.A., Misukonis M.A., Pisetsky D.S., and Weinberg J.B. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J. Exp. Med. 186 (1997) 365-373
19. Guix F.X., Uribesalgo I., Coma M., and Muñoz F.J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76 (2005) 126-152
20. Hanly J.G., and Liang M.H. Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann. N.Y. Acad. Sci. 823 (1997) 60-68
21. Hawn T.R., Wu H., Grossman J.M., Hahn B.H., Tsao B.P., and Aderem A. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10593-10597
22. Herkel J., Erez-Alon N., Mimran A., Wolkowicz R., Harmelin A., Ruiz P., Rotter V., and Cohen I.R. Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. Eur. J. Immunol. 30 (2000) 977-984
23. Hoffman S.A., Hoffman A.A., Shucard D.W., and Harbeck R.J. Antibodies to dissociated cerebellar cells in New Zealand mice as demonstrated by immunofluorescence. Brain Res. 10 142 (1978) 477-486
24. Hsu T.C., Chiang S.Y., Huang C.Y., Tsay G.J., Yang C.W., Huang C.N., and Tzang B.S. Beneficial effects of treatment with transglutaminase inhibitor cystamine on macrophage response in NZB/W F1 mice. Exp. Biol. Med. 232 (2007) 195-203
25. Hsu T.C., Chen Y.C., Lai W.X., Chiang S.Y., Huang C.Y., and Tzang B.S. Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice. Eur. J. Pharmacol. 591 (2008) 307-314
26. Hsu T.C., Huang C.Y., Chiang S.Y., Lai W.X., Tsai C.H., and Tzang B.S. Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice. Eur. J. Pharmacol. 579 (2008) 382-389
27. Ientile R., Campisi A., Raciti G., Caccamo D., Currò M., Cannavò G., Li Volti G., Macaione S., and Vanella A. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. J. Neurosci. Res. 74 (2003) 52-59
28. Ilangovan G., Osinbowale S., Bratasz A., Bonar M., Cardounel A.J., Zweier J.L., and Kuppusamy P. Heat shock regulates the respiration of cardiac H9c2 cells through upregulation of nitric oxide synthase. Am. J. Physiol., Cell Physiol. 287 (2004) C1472-1481
29. Jonsson H., Nived O., and Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine ( Baltimore ) 68 (1989) 141-150
30. Kaell A.T., Shetty M., Lee B.C., and Lockshin M.D. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients. Arch. Neurol. 43 (1986) 273-276
31. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., and Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 (2002) 143-149
32. Kuhn H.M., Kromminga A., Flammann H.T., Frey M., Layer P., and Arndt R. p53 autoantibodies in patients with autoimmune diseases: a quantitative approach. Autoimmunity 31 (1999) 229-235
33. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
34. Lai K.N., Leung J.C., Lai K.B., and Lai C.K. Effect of anti-DNA autoantibodies on the gene expression of interleukin 8, transforming growth factor-beta, and nitric oxide synthase in cultured endothelial cells. Scand. J. Rheumatol. 26 (1997) 461-467
35. Lesort M., Lee M., Tucholski J., and Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278 (2003) 3825-3830
36. Lorand L., and Conrad S.M. Transglutaminases. Mol. Cell. Biochem. 58 (1984) 9-35
37. McCune W.J., and Golbus J. Neuropsychiatric lupus. Rheum. Dis. Clin. North Am. 14 (1988) 149-167
38. Miret C., Molina R., Filella X., García-Carrasco M., Claver G., Ingelmo M., Ballesta A., and Font J. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Tumour Biol. 24 (2003) 185-188
39. Oates J.C., and Gilkeson G.S. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J. Investig. Med. 52 (2004) 62-71
40. Russell A.S., and Denman A.M. Normal induction and maintenance of tolerance in (NZBxNZW) F1 mice. Neuropsychiatric involvement in systemic lupus erythematosus. Clin. Exp. Immunol. 5 (1969) 265-272
41. Savarese E., Steinberg C., Pawar R.D., Reindl W., Akira S., Anders H.J., and Krug A. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58 (2008) 1107-1115
42. Shah V., Wiest R., Garcia-Cardena G., Cadelina G., Groszmann R.J., and Sessa W.C. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am. J. Physiol. 277 (1999) G463-468
43. Shin W.H., Park S.J., and Kim E.J. Protective effect of anthocyanins in middle cerebral artery occlusion and reperfusion model of cerebral ischemia in rats. Life Sci. 79 (2006) 130-137
44. Sibley J.T., Olszynski W.P., Decoteau W.E., and Sundaram M.B. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J. Rheumatol. 19 (1992) 47-52
45. Song Y., Zweier J.L., and Xia Y. Determination of the enhancing action of HSP90 on neuronal nitric oxide synthase by EPR spectroscopy. Am. J. Physiol., Cell Physiol. 281 (2001) C1819-C1824
46. Tzang B.S., Chiang S.Y., Lai W.X., Tsai C.C., Wu J.H., and Hsu T.C. Treatment with cystamine reduces apoptosis in liver from NZB/W F1 mice. Int. Immunopharmacol. 8 (2008) 589-596
47. Wigand R., Meyer J., Busse R., and Hecker M. Increased serum NG-hydroxy-l-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann. Rheum. Dis. 56 (1997) 330-332
48. Yan J., Chen C., Hu Q., Yang X., Lei J., Yang L., Wang K., Qin L., and Zhou C. The role of p53 in brain edema after 24 h of experimental subarachnoid hemorrhage in a rat model. Exp. Neurol. 214 (2008) 37-46